Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection

Abstract

BackgroundA vaccine is needed to prevent human immunodeficiency virus type 1 (HIV-1) infectionMethodsA double-blind, randomized trial of a recombinan